A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Trial Profile

A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Docetaxel
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Jan 2019.
    • 13 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 20 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top